Whilst we found no evidence for a direct role of Cav3.2 in driving or reversing trastuzumab-resistance, our data suggest that Cav3.2 may be an informative prognosis marker in ER+ breast cancer patients for overall survival and in HER2-positive breast cancer patients with chemotherapy. Here, ERBB2 is linked to breast carcinoma.